Get the Stockscreener App
2.73
0.37%
0.010
After Hours:
2.73
Arcadia Biosciences Inc stock is traded at $2.73, with a volume of 1,751.
It is up +0.37% in the last 24 hours and down -12.15% over the past month.
Arcadia Biosciences Inc is a producer and marketer of plant-based food and beverage products. It is engaged in science-based approaches to developing high-value crop improvements in wheat, soy, and hemp, designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health, and wellness products, and their viability for industrial applications. The company's consumer brands in the food, beverage, and body care categories include GoodWheat high-fiber pasta, Zola coconut water and others.
See More
Previous Close:
$2.72
Open:
$2.72
24h Volume:
1,751
Relative Volume:
0.21
Market Cap:
$3.72M
Revenue:
$5.67M
Net Income/Loss:
$-13.98M
P/E Ratio:
-0.127
EPS:
-21.5
Net Cash Flow:
$-15.30M
1W Performance:
-7.93%
1M Performance:
-12.15%
6M Performance:
+23.53%
1Y Performance:
-18.51%
1-Day Range:
$2.72
$2.79
1-Week Range:
$2.66
$3.055
52-Week Range:
$1.8512
$3.93
Arcadia Biosciences Inc Stock (RKDA) Company Profile
Name
Arcadia Biosciences Inc
Sector
Industry
Phone
530-756-7077
Address
202 COUSTEAU PLACE, DAVIS, CA
Arcadia Biosciences Inc Stock (RKDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-17-20 | Reiterated | H.C. Wainwright | Buy |
| May-12-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-09-15 | Initiated | Credit Suisse | Outperform |
| Jun-09-15 | Initiated | Piper Jaffray | Overweight |
Arcadia Biosciences Inc Stock (RKDA) Latest News
ARDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ardelyx, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Simplify Asset Management Inc. Buys 248,000 Shares of Ardelyx, Inc. (NASDAQ:ARDX) - MarketBeat
ARCA biopharma (NASDAQ:ABIO) Earns Sell Rating from Analysts at StockNews.com - Defense World
Ares Capital Co. (NASDAQ:ARCC) Receives $21.71 Consensus PT from Brokerages - Defense World
Seven Eight Capital LP Trims Stock Holdings in Ardelyx, Inc. (NASDAQ:ARDX) - Defense World
WINTON GROUP Ltd Sells 14,344 Shares of Acadia Healthcare Company, Inc. (NASDAQ:ACHC) - Defense World
Arcellx Sees Unusually Large Options Volume (NASDAQ:ACLX) - Defense World
Ardelyx (NASDAQ:ARDX) Trading Down 3.6% - Defense World
Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 3.5% - Defense World
Arko gains for a second day after report it's mulling sale of convenience stores - Seeking Alpha
Metric Deep Dive: Understanding Ares Capital Corp (ARCC) Through its Ratios - The Dwinnex
Aclaris Therapeutics (NASDAQ:ACRS) Receives “Neutral” Rating from HC Wainwright - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of “Buy” from Brokerages - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Acadia Healthcare Company, Inc.ACHC - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming DeadlinesARDX - PR Newswire
Aclaris Therapeutics (NASDAQ:ACRS) Receives "Neutral" Rating from HC Wainwright - MarketBeat
First Week of January 2027 Options Trading For Ares Capital (ARCC) - Nasdaq
Ares Capital Co. (NASDAQ:ARCC) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Ares Capital (ARCC) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Arcturus Therapeutics Holdings Inc (ARCT) expanding its growth trajectory ahead - SETE News
R1.3bn start to ARC’s financial year - Moneyweb
ARC Investments firms over 4% on strong portfolio growth - Moneyweb
Here's Why Investors Should Invest in Arcturus Stock Now - Zacks Investment Research
Recent Insider Activity Suggests Potential Gains for Arcutis Biotherapeutics Inc (ARQT) - Knox Daily
ARDX Investors Have Opportunity to Lead Ardelyx, Inc.Securities Fraud Lawsuit with the Schall Law Firm - Stockhouse Publishing
Arcturus Therapeutics Holdings Inc [ARCT] Insider Activity: An Update for Investors - Knox Daily
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of “Buy” by Brokerages - Defense World
ACHC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Acadia Healthcare Company, Inc. and Encourages Investors to Contact the Firm! - PR Newswire
Amendment: Arcadia Biosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits - Quantisnow
Wheat no longer in Arcadia’s future - Food Business News
Analysts Offer Predictions for Arcadia Biosciences, Inc.’s Q3 2024 Earnings (NASDAQ:RKDA) - Defense World
Arcadia shifting focus away from wheat - World Grain
Arcadia’s future no longer includes wheat - BakingBusiness.com
SPANISH COPY APPROVAL INTERACTIVE MEDIA SCHEDULED TEST Esheet # 54112387 / 5528413c - Business Wire
SEC Form 4 filed by Director Yoder Amy - Quantisnow
SEC Form 4 filed by Director Comcowich Kevin - Quantisnow
Arcadia Biosciences CEO acquires $1,442 in company stock By Investing.com - Investing.com Australia
Arcadia Biosciences CFO acquires $1.4k in company stock By Investing.com - Investing.com Australia
HC Wainwright Reiterates “Buy” Rating for Arcadia Biosciences (NASDAQ:RKDA) - Defense World
Arcadia Biosciences CFO acquires $1.4k in company stock By Investing.com - Investing.com Canada
Arcadia Biosciences CFO acquires $1.4k in company stock - Investing.com India
Arcadia Biosciences CEO acquires $1,442 in company stock - Investing.com India
Arcadia Biosciences CEO acquires $1,442 in company stock - Investing.com
Arcadia Biosciences CFO acquires $1.4k in company stock - Investing.com
Arcadia Biosciences CFO acquires $1.4k in company stock By Investing.com - Investing.com UK
Chief Financial Officer Kawakami Mark bought $1,442 worth of shares (700 units at $2.06), increasing direct ownership by 55% to 1,981 units (SEC Form 4) - Quantisnow
Chief Executive Officer Schaefer Thomas J. bought $1,442 worth of shares (700 units at $2.06), increasing direct ownership by 49% to 2,119 units (SEC Form 4) - Quantisnow
Arcadia Biosciences (NASDAQ:RKDA) Stock, Analyst Ratings, Price Targets, Forecasts - Benzinga
Arcadia Biosciences (STU:17D) Owner Earnings per Share (TTM) : -5.91 (As of Jun. 2024) - GuruFocus.com
Arcadia Biosciences (RKDA) to Participate in Upcoming Investor Conferences - Marketscreener.com
Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q2 2024 Earnings Call Transcript - Insider Monkey
Arcadia Biosciences Inc Stock (RKDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.08%
4.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):